Projet THERABOT (Horizon Europe, appel à projets 2023)
Action : Staff Exchanges
Panel : Life Sciences
Statut du projet : SIGNED

THERABOT pioneers a groundbreaking approach in the fight against cancer through the development of engineered biohybrid agents, iBots. These iBots represent a significant leap in bacterial cancer therapy (BCT), combining synthetic biology and nanotechnology to encapsulate therapeutic bacteria with protective polymeric coatings. This encapsulation aims to enhance the delivery and efficacy of bacteria to colonize tumor tissue, drastically reducing the adverse immune responses and systemic toxicity associated with traditional BCT. THERABOT's innovative strategy focuses on colorectal cancer, employing a multifaceted approach that includes the design of advanced intelligent biohybrids by programming iBots for targeted therapeutic action, and validating their effectiveness in vivo. Central to THERABOT's mission is its interdisciplinary and international consortium, comprising 12 members from 10 leading academic institutions and 2 SMEs across Europe (France, Spain and Sweden) and from non-EU countries (Japan, Argentina, Chile, Brazil and Thailand). This collaboration fosters a unique integration of diverse scientific disciplines, including bioengineering, immunology, material science and oncology, promoting the exchange of knowledge, techniques, and cultural perspectives, which is pivotal for addressing the complex challenges of developing a new cancer therapy. THERABOT not only emphasizes the scientific innovation but also prioritizes the training and career development of seconded staff, enhancing their research competencies and preparing them for future challenges in diverse fields. THERABOT's focus on developing accessible and patient-friendly cancer treatments, underscores its alignment with EU priorities in health and innovation. By redefining cancer treatment paradigms towards more precise, effective, and personalized approaches, our project aspires to have a lasting impact on society, improving patient outcomes, and contributing to the global fight against cancer.

Mots clés : synthetic biology bacterial cancer therapy polymer chemistry immunology and inflammation

Participants :
- A5 science (France) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 41400.0 €
- Universidade Federal de Juiz de Fora (Brésil) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université d'Uppsala (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 151800.0 €
- Indicate solutions, sl (Espagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 27600.0 €
- Institut national de la santé et de la recherche médicale (France) — Coordinator, beneficiary, Recherche, subvention : 915400.0 €
- Metropolitan University of Technology (Chili) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université de Tokyo (Japon) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Centre for Cooperative Research in Biomaterials (Espagne) — Partner, beneficiary, Recherche, subvention : 400200.0 €
- Sasin Graduate Institute of Business Administration of Chulalongkorn University (Thaïlande) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Universidad Nacional del Sur (Argentine) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Conseil national de la recherche scientifique et technique (Argentine) — Partner, associated partner, Recherche, subvention : 0.0 €
- Institut national des sciences et technologies industrielles avancées (Japon) — Partner, associated partner, Recherche, subvention : 0.0 €